A diagnostic accuracy study of targeted and systematic biopsies to detect clinically significant prostate cancer, including a model for the partial omission of systematic biopsies
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Morote, Juan
- dc.contributor.author Picola, Natàlia
- dc.contributor.author Muñoz-Rodríguez, Jesús
- dc.contributor.author Paesano, Nahuel
- dc.contributor.author Ruiz Plazas, Xavier
- dc.contributor.author Muñoz-Rivero, Marta V.
- dc.contributor.author Celma, Anna
- dc.contributor.author García de Manuel, Gemma
- dc.contributor.author Aisian, Ignacio
- dc.contributor.author Servian, Pol
- dc.contributor.author Abascal-Junquera, José María
- dc.date.accessioned 2024-04-30T06:12:43Z
- dc.date.available 2024-04-30T06:12:43Z
- dc.date.issued 2023
- dc.description.abstract The primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA > 3 ng/mL, and/or a suspicious digital rectal examination (DRE), who underwent targeted and systematic biopsies between 2021 and 2022. CsPCa (grade group 2 or higher) was detected in 1026 men (48.4%). Discrepancies in csPCa detection in targeted and systematic biopsies were observed in 49.6%, with 13.9% of csPCa cases being detected only in systematic biopsies and 35.7% only in targeted biopsies. A predictive model for csPCa detection only in targeted biopsies was developed from the independent predictors age (years), prostate volume (mL), PI-RADS score (3 to 5), mpMRI Tesla (1.5 vs. 3.0), TRUS-MRI fusion image technique (cognitive vs. software), and prostate biopsy route (transrectal vs. transperineal). The csPCa discrimination ability of targeted biopsies showed an AUC of 0.741 (95% CI 0.721-0.762). The avoidance rate of systematic prostate biopsies went from 0.5% without missing csPCa to 18.3% missing 4.6% of csPCa cases. We conclude that the csPCa diagnostic accuracy of targeted biopsies is higher than that of systematic biopsies. However, a significant rate of csPCa remains detected only in systematic biopsies. A predictive model for the partial omission of systematic biopsies was developed.
- dc.format.mimetype application/pdf
- dc.identifier.citation Morote J, Picola N, Muñoz-Rodriguez J, Paesano N, Ruiz-Plazas X, Muñoz-Rivero MV, et al. A diagnostic accuracy study of targeted and systematic biopsies to detect clinically significant prostate cancer, including a model for the partial omission of systematic biopsies. Cancers (Basel). 2023 Sep 13;15(18):4543. DOI: 10.3390/cancers15184543
- dc.identifier.doi http://dx.doi.org/10.3390/cancers15184543
- dc.identifier.issn 2072-6694
- dc.identifier.uri http://hdl.handle.net/10230/59950
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Cancers (Basel). 2023 Sep 13;15(18):4543
- dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Clinically significant prostate cancer detection
- dc.subject.keyword Prostate biopsy concordance
- dc.subject.keyword Systematic biopsy
- dc.subject.keyword Targeted biopsy
- dc.title A diagnostic accuracy study of targeted and systematic biopsies to detect clinically significant prostate cancer, including a model for the partial omission of systematic biopsies
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion